ARGAN INC·4

Jun 17, 4:30 PM ET

Getsinger Peter W 4

Research Summary

AI-generated summary

Updated

Argan (AGX) Director Peter Getsinger Exercises Options, Sells Shares

What Happened
Peter W. Getsinger, a director of Argan, Inc. (AGX), exercised stock options and promptly sold shares. On June 15, 2026 he exercised an option awarded Dec 16, 2022 to purchase 5,000 shares at $35.72 each (net-settle). As reported, 4,728 shares were acquired at $35.72 (cost ~$168,884) and then 4,728 shares were sold on June 16, 2026 for an average of $708.65 ($3,350,497). He also sold 2,000 additional shares on June 17, 2026 at an average of $699.00 ($1,398,000). Total open-market proceeds reported: ~$4.75 million.

Key Details

  • Transaction dates and prices:
    • 2026-06-15: Exercised option to purchase 5,000 shares at $35.72 (net-settle) — exercise cost ~$178,600 (footnote F1).
    • 2026-06-15: 4,728 shares reported acquired at $35.72 — $168,884 (transaction code M, footnote F1).
    • 2026-06-16: Sold 4,728 shares at an average $708.65 — proceeds ~$3,350,497 (footnote F2).
    • 2026-06-17: Sold 2,000 shares at an average $699.00 — proceeds $1,398,000 (footnote F3).
  • Shares owned after the transactions: not specified in the provided filing.
  • Notable footnotes: F1 confirms the June 15 exercise used the net-settle method (common for covering exercise cost/withholding). F2 and F3 describe the open-market sales on June 16–17.
  • Filing timeliness: Report filed June 17, 2026 for a 6/15/2026 transaction — appears to have been filed within the typical 2-business-day Form 4 window.

Context

  • This was an option exercise followed by immediate open-market sales (a common cashless/near-cashless pattern): options were exercised and shares were sold soon after. Such sales often reflect option liquidity or tax/exercise-related actions rather than a definitive view on the company’s outlook.
  • The largest items here are sales (total proceeds ~ $4.75M); purchases consist of the option exercise at a low strike ($35.72) relative to the sale prices (~$699–708), producing substantial realized gain on the exercised shares.